A5062403027- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Cancer survivorship and care
- COVID-19 and healthcare impacts
- Statistical Methods in Clinical Trials
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Neuroendocrine Tumor Research Advances
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Occupational and environmental lung diseases
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Neuroblastoma Research and Treatments
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
Ospedale Vito Fazzi
2023-2025
Ospedale San Luigi Gonzaga
2017-2023
University of Turin
2017-2023
A. O. Ordine Mauriziano di Torino
2020
(1.1) to evaluate the association between baseline 18F-FDG PET/CT semi-quantitative parameters of primary lesion with progression free survival (PFS), overall (OS) and response immunotherapy, in advanced non-small cell lung carcinoma (NSCLC) patients eligible for immunotherapy; (1.2) application radiomics analysis identify features predictive (1.3) if tumor burden assessed by (N M factors) is associated PFS OS.we retrospectively analyzed clinical records NCSLC (stage IIIb/c or stage IV)...
To assess time trends in the inclusion of health-related quality life (QoL) among study endpoints and reporting QoL results publications, randomised phase III oncology trials published between 2017 2021 were compared with previous 5 years. All issues 2012 by 11 major journals handsearched for primary publications adult patients solid tumours. Trials 2017-2021 2012-2016 three endpoints: (1) proportion including out all eligible publications; (2) presenting those (3) data publications. 388 446...
Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality life over docetaxel in patients with KRASp.G12C-mutated advanced non-small-cell lung cancer (NSCLC) within the CodeBreak-200 study. Here we report real-world efficacy tolerability data from NSCLC who received sotorasib Italian expanded access program (EAP).
The current study aims to investigate the practice of bone metastasis management in patients with non-small cell lung cancer. An online questionnaire was administered 92 oncologists. A survey developed and revised by dedicated experts composed five sections: i) general work characteristics, ii) diagnostic issues, bone-targeted agents iii) radiotherapy iv) supportive care issues. Descriptive statistics applied. 18F-FDG PET is preferred evaluation for skeletal assessment both (62 %) without...
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion achieve long-term survival, about one-third experience detrimental survival outcomes, including early death, hyperprogression, and fast progression. The impact clinical factors on progression (EP) development has not been widely explored. Methods: We designed retrospective, multicenter study involving five Italian centers, ≥ 50%,...
To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for stratification NSCLC patients, but harmonized procedures are required to optimize diagnostic workflow. In this context knowledge-based database (Biomarkers ATLAS, https://biomarkersatlas.com/) was developed by supervising group expert pathologists and thoracic oncologists collecting updated...